岭南现代临床外科2025，Vol.25Issue(4)：273-280,8.DOI:10.3969/j.issn.1009-976X.2025.04.010
乳腺癌新辅助治疗后豁免手术研究进展
Research progress on surgical omission after neoadjuvant therapy for breast cancer
摘要
Abstract
In the context of modern multidisciplinary therapy,the improvement of neoadjuvant therapy(NAT)has increased the pathologic complete response(pCR)rate in breast cancer patients.Compared to patients with residual disease,those achieving pCR demonstrate superior prognosis.Accurate non-surgical identification of pCR patients may allow for the omission of breast surgery,but the success of this strategy hinges on diagnostic precision.Preliminary data exist regarding the accuracy of vacuum-assisted breast biopsy(VABB)for assessing tumor response after neoadjuvant therapy in early-stage breast cancer,as well as the feasibility of omitting surgery based on biopsy findings.However,several unresolved issues remain regarding breast surgery omission after NAT,and further clinical trial validation is needed.This review aims to explore the feasibility of omitting breastsurgery in patients who achieve pCR after neoadjuvant therapy.关键词
乳腺癌/新辅助治疗/豁免手术Key words
breast cancer/neoadjuvant therapy/omission of surgery分类
医药卫生引用本文复制引用
严孟欣,陈翔..乳腺癌新辅助治疗后豁免手术研究进展[J].岭南现代临床外科,2025,25(4):273-280,8.基金项目
白求恩·医学科学研究基金(2022-YJ-085-J-Z-ZZ-005) （2022-YJ-085-J-Z-ZZ-005）
